<scp>PD</scp> ‐1/ <scp>PD</scp> ‐ <scp>L1</scp> Checkpoint Dysfunction in Vitiligo: Novel Pathogenic Insights and Therapeutic Innovation

Vitiligo, a chronic autoimmune disorder characterized by progressive melanocyte destruction, remains challenging to treat due to an incomplete understanding of underlying immune mechanisms. Recent clinical observations from cancer immunotherapy have revealed an unexpected connection between vitiligo and immune checkpoint pathways. The development of vitiligo-like depigmentation in up to 25% of cancer patients receiving anti-PD-1/PD-L1 therapy provides compelling evidence that checkpoint dysfunction drives melanocyte autoimmunity. This review synthesizes emerging evidence demonstrating that vitiligo is characterized by a cascade of interconnected checkpoint failures: elevated PD-1 expression on chronically activated T cells, profound PD-L1 deficiency in melanocytes, compromised regulatory T cell function, and critically, the failure of vitiligo melanocytes to upregulate protective PD-L1 in response to interferon-gamma. This creates a vicious cycle where inflammatory cytokines drive melanocyte destruction without triggering natural protective responses. We propose a novel pathogenic framework positioning vitiligo as a disease of multiple simultaneous checkpoint failures affecting effector control, target protection, and regulatory oversight. This understanding reveals rational therapeutic strategies using checkpoint agonists to restore immune tolerance. Preclinical evidence demonstrates that PD-L1 fusion proteins can reverse depigmentation in mouse models, while next-generation melanocyte-targeted therapies promise localized effects with minimal systemic immunosuppression. These insights reframe vitiligo pathogenesis and provide mechanistic rationale for novel immunomodulatory treatments targeting checkpoint restoration.